ClearB Therapeutics

Executive Summary

ClearB Therapeutics is a private biotech company developing a novel therapeutic vaccine aimed at achieving a functional cure for chronic hepatitis B virus (HBV) infection. The vaccine is designed to redirect the patient's immune system to recognize and eliminate HBV-infected liver cells, potentially offering a durable treatment option without lifelong antiviral therapy. Chronic HBV affects over 250 million people worldwide and current treatments rarely achieve cure, underscoring the unmet medical need. ClearB's approach leverages proprietary antigen design and formulation to enhance T-cell responses against multiple HBV antigens, with the goal of inducing sustained viral control after a finite treatment course.

Upcoming Catalysts (preview)

• Q3 2026IND approval and Phase 1 trial initiation60% success
• Q1 2027Interim safety and immunogenicity data from Phase 140% success
• Q4 2026Partnership or licensing deal for late-stage development30% success